A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
The main objective of this study is to compare conventional chemotherapy: daunorubicin and the Aracytine and this chemotherapy in combination with the monoclonal antibody used Mylotarg in divided doses.
Study Type: Interventional (Clinical Trial)
Actual Enrollment: 280 participants
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase III Multicentric Randomized Study of the Combination of Repeated Doses of Gemtuzumab Ozogamicin (GO) With Daunorubicin and Cytarabine Versus Daunorubicin and Cytarabine in Untreated Patients With Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old.
Study Start Date: December 2007
Actual Primary Completion Date: July 2011
Actual Study Completion Date: July 2013
- Active Comparator: Arm A Daunorubicin and Cytarabine
- Experimental: Arm B Daunorubicin and Cytarabine and Mylotarg
|Date last updated at source||2013-07-11|
|Study start date||2007-12-01|
|Estimated primary completion date||2011-07-01|